Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pasithea Therapeutics Corp. - Common Stock (NQ: KTTA )

2.790 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pasithea Therapeutics Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition
Pasithea Therapeutics Corp. (NASDAQ: KTTA) recently announced the availability of an AUD $1 million (USD $694,000) drug development research award following the Company's acquisition of Alpha-5... 
Via Benzinga
Pasithea Therapeutics Awarded A Drug Development Research Grant
-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. $694,000 of non-dilutive funding -- 
Via Benzinga
This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop?
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotech company with a goal of investigating novel drug treatments to provide more effective relief to the estimated 792 million people around the world... 
Via Benzinga
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5
From Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via Business Wire
EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition
Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for amyotrophic lateral sclerosis (ALS)... 
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
Pasithea Biotech Reports That It's Aiming To Be At The Forefront Of The Mental Health Revolution
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Virtual Reality Technologies Are Reportedly Unlocking New Possibilities For Mental Healthcare
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Pasithea Reveals Cash Position Of $52.9 Million In Latest Earnings Report, To Expand Pipeline And Fund Operations Well Into 2024
Image sourced from Pixabay 
Via Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Pasithea Partners With Glimpse Group To Co-Develop VR Environments For Patients With Psychiatric Disorders
Photo by Maxim Hopman on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric... 
Via FinancialNewsMedia
Topics Economy
Exposures Economy
EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders
Pasithea Therapeutics Corp (NASDAQ: KTTA) has partnered with Glimpse Group Inc (NASDAQ: VRAR), a Virtual Reality and Augmented Reality (VR / AR) platform company, and its... 
Via Benzinga
This Company Reports Using Ketamine To Treat Mental Health Disorders
Photo by Sydney Sims on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.... 
Via Benzinga
Pasithea To Open 3 New Clinics In The U.K. For Patients with Mental Health Issues, Each Clinic Expected To Add ~$5 Million In Annual Revenue
Image by Christina on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Pasithea... 
Via Benzinga
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Exposures COVID-19
Pasithea Therapeutics Announces Plans To Open Three New Clinics In The UK By Mid-2022
-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX)... 
Via Benzinga
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,... 
Via FinancialNewsMedia
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 338.2% to $2.82 during Thursday's pre-market session. The market value of their outstanding shares is at $284.5... 
Via Benzinga
EXCLUSIVE: Pasithea Therapeutics Starts New Multiple Sclerosis Vaccine Development Program
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced a new chemical entity (NCE) development program and named Massachusetts-based Hooke Laboratories as its research partner. 
Via Benzinga
From Mobile Clinics to Drug Development, This Company Is Attempting to Tackle Brain Disorders and Promote Mental Health Advances
Photo by David Matos on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; News Corp To Buy Base Chemicals
Following the market opening Monday, the Dow traded up 0.39% to 36,089.53 while the NASDAQ rose 0.78% to 15,774.78. The S&P also rose, gaining 0.70% to 4,758.97. The U.S. has... 
Via Benzinga
54 Biggest Movers From Thursday
Gainers 22nd Century Group, Inc. (NASDAQ: XXII) surged 38.6% to settle at $3.05. The FDA authorized marketing of tobacco products that help reduce exposure to and consumption of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.